Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01344993 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration
A Phase 1 study, sponsored by Astellas Institute for Regenerative Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01344993 is a Phase 1 study that has completed, run by Astellas Institute for Regenerative Medicine. The registered enrollment target is 13 participants.
The verdict
NCT01344993, a Phase 1 study, has completed, sponsored by Astellas Institute for Regenerative Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a safety and tolerability trial to evaluate the effect of subretinal injection of human embryonic stem cell derived retinal pigment epithelium cells in patients with dry Age Related Macular Degeneration (AMD) and to perform exploratory evaluation of potential efficacy endpoints to be used in future studies retinal pigment epithelium (RPE) cellular therapy.
Interventions
- BIOLOGICAL MA09-hRPE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2011-06-09 |
| Est. Completion | 2015-08-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01344993
The ClinicalTrials.gov registry entry for NCT01344993 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Institute for Regenerative Medicine, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MA09-hRPE is the first listed.
NCT01344993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01344993 about?
NCT01344993 is a clinical study titled "Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration". This is a safety and tolerability trial to evaluate the effect of subretinal injection of human embryonic stem cell derived retinal pigment epithelium cells in patients with dry Age Related Macular Degeneration (AMD) and to perform exploratory evaluation of potential efficacy endpoints to be used in...
What is the current status of trial NCT01344993?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2011-06-09. Estimated completion is 2015-08-19.
What interventions are being tested in trial NCT01344993?
The interventions under investigation include: MA09-hRPE (BIOLOGICAL).
Who is sponsoring clinical trial NCT01344993?
This trial is sponsored by Astellas Institute for Regenerative Medicine, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.